Giovanni Gravina1, Federica Ferrari2, Grazia Nebbiai3. 1. Center for Eating Behaviour and Metabolism Disorders, Casa di Cura San Rossore, Pisa, Italy. gravina@sanrossorecura.it. 2. Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, Pisa, Italy. 3. Center for Eating Behaviour and Metabolism Disorders, Casa di Cura San Rossore, Pisa, Italy.
Abstract
BACKGROUND: Obesity has been proven to be a risk factor for type 2 diabetes mellitus (T2DM) through numerous pathogenetic mechanisms. Unexpectedly, some studies suggest that subjects with overweight/obesity and T2DM have better clinical outcome than their normal weight peers. This finding is described as "obesity paradox" and calls into question the importance of weight loss in this specific population. OBJECTIVE: This article is a narrative overview on the obesity and type 2 diabetes mellitus, particularly regarding the obesity paradox in T2DM patients. METHODS: We used as sources MEDLINE/PubMed, CINAHL, EMBASE, and Cochrane Library, from inception to March 2020; we chose 30 relevant papers regarding the association of obesity with clinical outcome and mortality of patients affected by T2DM. RESULTS: Many studies report that in patients with T2DM, overweight and obesity are associated with a better prognosis than underweight or normal weight, suggesting the presence of an obesity paradox. However, these studies have numerous limitations due to their mainly retrospective nature and to numerous confounding factors, such as associated pathologies, antidiabetic treatments, smoking habit, lack of data about distribution of body fat or weight history. CONCLUSION: Literature data regarding the phenomenon of obesity paradox in T2DM patients are controversial due to the several limitations of the studies; therefore in the management of patients with overweight/obesity and T2DM is recommended referring to the established guidelines, which indicate diet and physical activity as the cornerstone of the treatment. LEVEL OF EVIDENCE: Level V: narrative review.
BACKGROUND:Obesity has been proven to be a risk factor for type 2 diabetes mellitus (T2DM) through numerous pathogenetic mechanisms. Unexpectedly, some studies suggest that subjects with overweight/obesity and T2DM have better clinical outcome than their normal weight peers. This finding is described as "obesity paradox" and calls into question the importance of weight loss in this specific population. OBJECTIVE: This article is a narrative overview on the obesity and type 2 diabetes mellitus, particularly regarding the obesity paradox in T2DM patients. METHODS: We used as sources MEDLINE/PubMed, CINAHL, EMBASE, and Cochrane Library, from inception to March 2020; we chose 30 relevant papers regarding the association of obesity with clinical outcome and mortality of patients affected by T2DM. RESULTS: Many studies report that in patients with T2DM, overweight and obesity are associated with a better prognosis than underweight or normal weight, suggesting the presence of an obesity paradox. However, these studies have numerous limitations due to their mainly retrospective nature and to numerous confounding factors, such as associated pathologies, antidiabetic treatments, smoking habit, lack of data about distribution of body fat or weight history. CONCLUSION: Literature data regarding the phenomenon of obesity paradox in T2DM patients are controversial due to the several limitations of the studies; therefore in the management of patients with overweight/obesity and T2DM is recommended referring to the established guidelines, which indicate diet and physical activity as the cornerstone of the treatment. LEVEL OF EVIDENCE: Level V: narrative review.
Entities:
Keywords:
Obesity; Obesity paradox; Type 2 diabetes
Authors: Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks Journal: JAMA Date: 2003-01-01 Impact factor: 56.272
Authors: James B Meigs; Martin K Rutter; Lisa M Sullivan; Caroline S Fox; Ralph B D'Agostino; Peter W F Wilson Journal: Diabetes Care Date: 2007-01-26 Impact factor: 19.112
Authors: M Roden; T B Price; G Perseghin; K F Petersen; D L Rothman; G W Cline; G I Shulman Journal: J Clin Invest Date: 1996-06-15 Impact factor: 14.808
Authors: Alexandra E Butler; Juliette Janson; Susan Bonner-Weir; Robert Ritzel; Robert A Rizza; Peter C Butler Journal: Diabetes Date: 2003-01 Impact factor: 9.461
Authors: Mariel M Finucane; Gretchen A Stevens; Melanie J Cowan; Goodarz Danaei; John K Lin; Christopher J Paciorek; Gitanjali M Singh; Hialy R Gutierrez; Yuan Lu; Adil N Bahalim; Farshad Farzadfar; Leanne M Riley; Majid Ezzati Journal: Lancet Date: 2011-02-03 Impact factor: 79.321
Authors: Konstantinos Georgiou; Nikolay A Belev; Tilemachos Koutouratsas; Hector Katifelis; Maria Gazouli Journal: World J Gastrointest Pathophysiol Date: 2022-05-22
Authors: Per Wändell; Axel C Carlsson; Anders Larsson; Olle Melander; Torgny Wessman; Johan Ärnlöv; Toralph Ruge Journal: Ups J Med Sci Date: 2021-09-16 Impact factor: 2.384